Ductal access for prevention and therapy of mammary tumors

Satoshi Murata, Scott Kominsky, Mustafa Vali, Zhe Zhang, Elizabeth Garrett-Mayer, Dorian Korz, David Huso, Sharyn D. Baker, James Barber, Elizabeth Jaffee, R. Todd Reilly, Saraswati Sukumar

Research output: Contribution to journalArticle

Abstract

In cancer patients and in those at high risk, systemic exposure to agents for therapy or prevention is accompanied by undesirable side effects. We hypothesized that it is possible to prevent and treat breast cancer by introducing anticancer agents into the mammary ductal network. Here, we show the efficacy of intraductally administered anticancer agents 4-hydroxytamoxifen and pegylated liposomal doxorubicin (PLD) in the prevention and treatment of breast cancer using the rat N-methyl-N′-nitrosourea-induced and spontaneous HER-2/neu transgenic mouse (neu-N) models of breast cancer. Intraductal administration of PLD to neu-N mice caused regression of established tumors and prevented tumor development more effectively than i.v. injection (P <0.0001). Intraductal administration resulted in lower circulating levels of PLD compared with i.V. administration, with no evidence of systemic toxicity or long-term histopathologic changes in the mammary gland. Compared with systemic administration, intraductal injection provides direct access to breast lesions with higher local and lower systemic drug exposure. These studies suggest that this approach has potential for application to prevention and neoadjuvant therapy of early breast cancer.

Original languageEnglish (US)
Pages (from-to)638-645
Number of pages8
JournalCancer Research
Volume66
Issue number2
DOIs
StatePublished - Jan 15 2006

Fingerprint

Breast Neoplasms
Antineoplastic Agents
Breast
Methylnitrosourea
Neoplasms
Injections
Neoadjuvant Therapy
Therapeutics
Human Mammary Glands
Transgenic Mice
Pharmaceutical Preparations
liposomal doxorubicin
afimoxifene

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ductal access for prevention and therapy of mammary tumors. / Murata, Satoshi; Kominsky, Scott; Vali, Mustafa; Zhang, Zhe; Garrett-Mayer, Elizabeth; Korz, Dorian; Huso, David; Baker, Sharyn D.; Barber, James; Jaffee, Elizabeth; Reilly, R. Todd; Sukumar, Saraswati.

In: Cancer Research, Vol. 66, No. 2, 15.01.2006, p. 638-645.

Research output: Contribution to journalArticle

Murata, S, Kominsky, S, Vali, M, Zhang, Z, Garrett-Mayer, E, Korz, D, Huso, D, Baker, SD, Barber, J, Jaffee, E, Reilly, RT & Sukumar, S 2006, 'Ductal access for prevention and therapy of mammary tumors', Cancer Research, vol. 66, no. 2, pp. 638-645. https://doi.org/10.1158/0008-5472.CAN-05-4329
Murata S, Kominsky S, Vali M, Zhang Z, Garrett-Mayer E, Korz D et al. Ductal access for prevention and therapy of mammary tumors. Cancer Research. 2006 Jan 15;66(2):638-645. https://doi.org/10.1158/0008-5472.CAN-05-4329
Murata, Satoshi ; Kominsky, Scott ; Vali, Mustafa ; Zhang, Zhe ; Garrett-Mayer, Elizabeth ; Korz, Dorian ; Huso, David ; Baker, Sharyn D. ; Barber, James ; Jaffee, Elizabeth ; Reilly, R. Todd ; Sukumar, Saraswati. / Ductal access for prevention and therapy of mammary tumors. In: Cancer Research. 2006 ; Vol. 66, No. 2. pp. 638-645.
@article{ec7c16ec5f0a4a36a544f171cbec33ad,
title = "Ductal access for prevention and therapy of mammary tumors",
abstract = "In cancer patients and in those at high risk, systemic exposure to agents for therapy or prevention is accompanied by undesirable side effects. We hypothesized that it is possible to prevent and treat breast cancer by introducing anticancer agents into the mammary ductal network. Here, we show the efficacy of intraductally administered anticancer agents 4-hydroxytamoxifen and pegylated liposomal doxorubicin (PLD) in the prevention and treatment of breast cancer using the rat N-methyl-N′-nitrosourea-induced and spontaneous HER-2/neu transgenic mouse (neu-N) models of breast cancer. Intraductal administration of PLD to neu-N mice caused regression of established tumors and prevented tumor development more effectively than i.v. injection (P <0.0001). Intraductal administration resulted in lower circulating levels of PLD compared with i.V. administration, with no evidence of systemic toxicity or long-term histopathologic changes in the mammary gland. Compared with systemic administration, intraductal injection provides direct access to breast lesions with higher local and lower systemic drug exposure. These studies suggest that this approach has potential for application to prevention and neoadjuvant therapy of early breast cancer.",
author = "Satoshi Murata and Scott Kominsky and Mustafa Vali and Zhe Zhang and Elizabeth Garrett-Mayer and Dorian Korz and David Huso and Baker, {Sharyn D.} and James Barber and Elizabeth Jaffee and Reilly, {R. Todd} and Saraswati Sukumar",
year = "2006",
month = "1",
day = "15",
doi = "10.1158/0008-5472.CAN-05-4329",
language = "English (US)",
volume = "66",
pages = "638--645",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Ductal access for prevention and therapy of mammary tumors

AU - Murata, Satoshi

AU - Kominsky, Scott

AU - Vali, Mustafa

AU - Zhang, Zhe

AU - Garrett-Mayer, Elizabeth

AU - Korz, Dorian

AU - Huso, David

AU - Baker, Sharyn D.

AU - Barber, James

AU - Jaffee, Elizabeth

AU - Reilly, R. Todd

AU - Sukumar, Saraswati

PY - 2006/1/15

Y1 - 2006/1/15

N2 - In cancer patients and in those at high risk, systemic exposure to agents for therapy or prevention is accompanied by undesirable side effects. We hypothesized that it is possible to prevent and treat breast cancer by introducing anticancer agents into the mammary ductal network. Here, we show the efficacy of intraductally administered anticancer agents 4-hydroxytamoxifen and pegylated liposomal doxorubicin (PLD) in the prevention and treatment of breast cancer using the rat N-methyl-N′-nitrosourea-induced and spontaneous HER-2/neu transgenic mouse (neu-N) models of breast cancer. Intraductal administration of PLD to neu-N mice caused regression of established tumors and prevented tumor development more effectively than i.v. injection (P <0.0001). Intraductal administration resulted in lower circulating levels of PLD compared with i.V. administration, with no evidence of systemic toxicity or long-term histopathologic changes in the mammary gland. Compared with systemic administration, intraductal injection provides direct access to breast lesions with higher local and lower systemic drug exposure. These studies suggest that this approach has potential for application to prevention and neoadjuvant therapy of early breast cancer.

AB - In cancer patients and in those at high risk, systemic exposure to agents for therapy or prevention is accompanied by undesirable side effects. We hypothesized that it is possible to prevent and treat breast cancer by introducing anticancer agents into the mammary ductal network. Here, we show the efficacy of intraductally administered anticancer agents 4-hydroxytamoxifen and pegylated liposomal doxorubicin (PLD) in the prevention and treatment of breast cancer using the rat N-methyl-N′-nitrosourea-induced and spontaneous HER-2/neu transgenic mouse (neu-N) models of breast cancer. Intraductal administration of PLD to neu-N mice caused regression of established tumors and prevented tumor development more effectively than i.v. injection (P <0.0001). Intraductal administration resulted in lower circulating levels of PLD compared with i.V. administration, with no evidence of systemic toxicity or long-term histopathologic changes in the mammary gland. Compared with systemic administration, intraductal injection provides direct access to breast lesions with higher local and lower systemic drug exposure. These studies suggest that this approach has potential for application to prevention and neoadjuvant therapy of early breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=31544470043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544470043&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-4329

DO - 10.1158/0008-5472.CAN-05-4329

M3 - Article

C2 - 16423990

AN - SCOPUS:31544470043

VL - 66

SP - 638

EP - 645

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 2

ER -